{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:58:52Z","timestamp":1790276332433,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Living Legacy Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Optimal valganciclovir dosing for cytomegalovirus (CMV) prophylaxis in solid-organ transplant (SOT) patients on continuous veno-venous hemodialysis (CVVHD) is not known. Ganciclovir trough concentrations \u22650.60 \u03bcg\/mL have been suggested for CMV prophylaxis. This study was conducted to determine if valganciclovir 450 mg enterally every 24 hours achieves ganciclovir trough concentrations \u22650.60 \u03bcg\/mL in patients on CVVHD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-center, prospective, open-label, pharmacokinetic study included adult SOT patients admitted to an intensive care unit from March 2018 to June 2019 on CVVHD. All patients were receiving valganciclovir 450 mg enterally every 24 hours for CMV prophylaxis prior to enrollment. Each patient had a peak and trough sample drawn at steady state.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten SOT patients were included in the study (6 liver, 1 simultaneous liver-kidney, 2 bilateral lung, 1 heart). The mean \u00b1 SD age was 51.8 \u00b1 14.0 years, and average body mass index was 27 \u00b1 6.9 kg\/m2. Ganciclovir trough concentrations ranged from 0.31 to 3.16 \u03bcg\/mL, and 80% of participants have trough concentrations \u22650.60 \u03bcg\/mL. No patients had documented neutropenia while on valganciclovir and CVVHD; 60% of patients had significant thrombocytopenia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Valganciclovir 450 mg enterally every 24 hours achieved ganciclovir trough concentrations \u22650.60 \u03bcg\/mL in most patients on CVVHD, similar to those reported with intravenous ganciclovir for prophylaxis in this population. Based on these data, valganciclovir may require dosing every 24 hours to achieve concentrations equivalent to ganciclovir. Neutropenia did not occur in the study period. Thrombocytopenia was common and likely multifactorial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa537","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T19:09:33Z","timestamp":1588360173000},"page":"101-106","source":"Crossref","is-referenced-by-count":10,"title":["Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-9473","authenticated-orcid":false,"given":"Andrew S","family":"Jarrell","sequence":"first","affiliation":[{"name":"The Johns Hopkins Hospital, Department of Pharmacy, Division of Critical Care and Surgery, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R","family":"Crow","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Department of Pharmacy, Division of Critical Care and Surgery, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Strout","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Department of Pharmacy, Division of Critical Care and Surgery, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M","family":"Kruer","sequence":"additional","affiliation":[{"name":"Indiana University Health\u2013Adult Academic Health Center, Department of Pharmacy, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey P","family":"Toman","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Department of Pharmacy, Division of Critical Care and Surgery, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V","family":"Dioverti-Prono","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lees","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Department of Pharmacy, Division of Critical Care and Surgery, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, Maryland, USA"},{"name":"Johns Hopkins University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"2021070111153588000_CIT0001","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2021070111153588000_CIT0002","volume-title":"Cytovene-IV\u00ae [package insert]","year":"2016"},{"key":"2021070111153588000_CIT0003","volume-title":"Valcyte\u00ae [package insert]","year":"2015"},{"key":"2021070111153588000_CIT0004","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study","volume":"18","author":"Young","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2021070111153588000_CIT0005","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"2021070111153588000_CIT0006","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","article-title":"Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients","volume":"8","author":"Chamberlain","year":"2008","journal-title":"Am J Transplant"},{"key":"2021070111153588000_CIT0007","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/infdis\/174.1.188","article-title":"Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS","volume":"174","author":"Piketty","year":"1996","journal-title":"J Infect Dis"},{"key":"2021070111153588000_CIT0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"2021070111153588000_CIT0009","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"2021070111153588000_CIT0010","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.1987.03390220080025","article-title":"Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts","volume":"257","author":"Erice","year":"1987","journal-title":"JAMA"},{"key":"2021070111153588000_CIT0011","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkn102","article-title":"Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients","volume":"61","author":"Perrottet","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2021070111153588000_CIT0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199304000-00006","article-title":"Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis","volume":"15","author":"Boulieu","year":"1993","journal-title":"Ther Drug Monit"},{"key":"2021070111153588000_CIT0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02425056","article-title":"Clinical use of ganciclovir during renal failure and continuous hemodialysis","volume":"20","author":"Bastien","year":"1994","journal-title":"Intensive Care Med"},{"key":"2021070111153588000_CIT0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00003246-199801000-00038","article-title":"Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration","volume":"26","author":"Gando","year":"1998","journal-title":"Crit Care Med"},{"key":"2021070111153588000_CIT0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.00892-13","article-title":"Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients","volume":"58","author":"Horvatits","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070111153588000_CIT0016","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.transproceed.2007.10.007","article-title":"Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation","volume":"39","author":"Pescovitz","year":"2007","journal-title":"Transplant Proc"},{"key":"2021070111153588000_CIT0017","volume-title":"Guidance for industry: bioanalytical method validation","author":"US Department of Health and Human Services, US Food and Drug Administration","year":"2001"},{"key":"2021070111153588000_CIT0018","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Inter Suppl"},{"key":"2021070111153588000_CIT0019","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccc.2006.02.011","article-title":"Pharmacokinetic changes in critical illness","volume":"22","author":"Boucher","year":"2006","journal-title":"Crit Care Clin"},{"key":"2021070111153588000_CIT0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/sur.2014.180","article-title":"Antimicrobial pharmacokinetics and pharmacodynamics","volume":"16","author":"Jarrell","year":"2015","journal-title":"Surg Infect (Larchmt)"},{"key":"2021070111153588000_CIT0021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1378\/chest.10-2243","article-title":"The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review","volume":"139","author":"Hui","year":"2011","journal-title":"Chest"},{"key":"2021070111153588000_CIT0022","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1378\/chest.115.5.1363","article-title":"Thrombocytopenia in a surgical ICU","volume":"115","author":"St\u00e9phan","year":"1999","journal-title":"Chest"},{"key":"2021070111153588000_CIT0023","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00007890-199903150-00010","article-title":"Thrombocytopenia after liver transplantation","volume":"67","author":"Chatzipetrou","year":"1999","journal-title":"Transplantation"},{"key":"2021070111153588000_CIT0024","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1060028018779200","article-title":"Evaluation of thrombocytopenia in critically ill patients receiving continuous renal replacement therapy","volume":"52","author":"Droege","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2021070111153588000_CIT0025","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3109\/0886022X.2015.1057799","article-title":"The incidence of thrombocytopenia associated with continuous renal replacement therapy in critically ill patients","volume":"37","author":"Ferreira","year":"2015","journal-title":"Ren Fail"},{"key":"2021070111153588000_CIT0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?","volume":"26","author":"Scott","year":"2004","journal-title":"Ther Drug Monit"},{"key":"2021070111153588000_CIT0027","doi-asserted-by":"crossref","first-page":"e01855","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa537\/33517451\/ciaa537.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/1\/101\/38846768\/ciaa537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/1\/101\/38846768\/ciaa537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T11:54:07Z","timestamp":1625140447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/1\/101\/5831845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa537","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,5,7]]}}}